ATM and neoplasm: An exploratory analysis in cohort A of the PROfound trial (patients with BRCA or ATM alterations detected via circulating tumor DNA [ctDNA]) confirmed prolonged median radiographic PFS in the olaparib arm, supporting the clinical utility of ctDNA as an alternative to tissue‐based genotyping for BRCA/ATM alterations [155].